- Home
- SRBK vs ATOS Comparison
SRBK vs ATOS Comparison
Compare SRBK & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRBK
- ATOS
- Stock Information
- Founded
- SRBK 1887
- ATOS 2009
- Country
- SRBK United States
- ATOS United States
- Employees
- SRBK N/A
- ATOS N/A
- Industry
- SRBK
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- SRBK
- ATOS Health Care
- Exchange
- SRBK Nasdaq
- ATOS Nasdaq
- Market Cap
- SRBK 117.4M
- ATOS 107.2M
- IPO Year
- SRBK N/A
- ATOS 2012
- Fundamental
- Price
- SRBK $15.00
- ATOS $0.87
- Analyst Decision
- SRBK
- ATOS Strong Buy
- Analyst Count
- SRBK 0
- ATOS 3
- Target Price
- SRBK N/A
- ATOS $6.17
- AVG Volume (30 Days)
- SRBK 30.3K
- ATOS 459.7K
- Earning Date
- SRBK 10-25-2025
- ATOS 11-11-2025
- Dividend Yield
- SRBK 1.36%
- ATOS N/A
- EPS Growth
- SRBK N/A
- ATOS N/A
- EPS
- SRBK 0.44
- ATOS N/A
- Revenue
- SRBK $31,833,000.00
- ATOS N/A
- Revenue This Year
- SRBK N/A
- ATOS N/A
- Revenue Next Year
- SRBK N/A
- ATOS N/A
- P/E Ratio
- SRBK $33.34
- ATOS N/A
- Revenue Growth
- SRBK 39.53
- ATOS N/A
- 52 Week Low
- SRBK $10.33
- ATOS $0.55
- 52 Week High
- SRBK $15.22
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- SRBK 58.88
- ATOS 64.66
- Support Level
- SRBK $14.60
- ATOS $0.81
- Resistance Level
- SRBK $15.11
- ATOS $0.85
- Average True Range (ATR)
- SRBK 0.20
- ATOS 0.03
- MACD
- SRBK -0.04
- ATOS 0.01
- Stochastic Oscillator
- SRBK 73.33
- ATOS 91.30
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.